Logotype for Axsome Therapeutics Inc

Axsome Therapeutics (AXSM) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Axsome Therapeutics Inc

Q3 2026 earnings summary

2 Nov, 2026

Executive summary

  • Q3 revenue was $259.7M, up 52% YoY and 19% sequentially; annualized commercial revenue run rate exceeded $1B.

  • AUVELITY led commercial growth, while development advanced across CNS indications, including seven Phase 3 trials.

Financial highlights

  • Q3 product sales were $250.0M and royalty plus milestone revenue was $9.7M, including an $8.5M SUNOSI milestone; total revenue was $259.7M versus $171.0M a year earlier.

  • AUVELITY sales were $207.6M, up 53% YoY; SUNOSI revenue was $48.2M, up 47%; SYMBRAVO sales were $3.9M, up 88%.

  • R&D expense was $50.6M versus $40.2M; SG&A was $203.1M versus $150.2M; cost of revenue was $17.8M versus $11.9M.

  • Net loss narrowed to $12.9M, or $0.25/share, from $47.2M, or $0.94/share; Q3 loss included $26.4M of stock-based compensation.

Outlook and guidance

  • No specific Q4 or 2027 revenue guidance; Q4 was tracking to expectations for continued AUVELITY growth across MDD and Alzheimer’s agitation.

  • Cash is expected to fund anticipated operations into cash flow positivity under the current operating plan; R&D and SG&A expenses are expected to rise as trials and commercialization continue.

  • AUVELITY gross-to-net discounts were in the mid-to-high 40% range in Q3, with a slight Q4 increase expected from seasonal accruals; 2027 is expected to be similar to 2026.

  • Milestones include ENGAGE BED results in Q1 2027, AXS-12 FDA action by May 1, 2027, and multiple solriamfetol and AXS-05 readouts in 2H 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Axsome Therapeutics